Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 219

Showing 1-25 of 219 citing articles:

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 655
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dominik Dahl, Yukiko Onishi, Paul Norwood, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 534-534
Open Access | Times Cited: 357
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 273
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 211
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Tim Heise, Andrea Mari, J. Hans DeVries, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 418-429
Closed Access | Times Cited: 164
Insulin resistance and insulin sensitizing agents
Lucia Mastrototaro, Michael Roden
Metabolism (2021) Vol. 125, pp. 154892-154892
Open Access | Times Cited: 162
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 125
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 114
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
Tito Borner, Caroline E. Geisler, Samantha M. Fortin, et al.
Diabetes (2021) Vol. 70, Iss. 11, pp. 2545-2553
Open Access | Times Cited: 103
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Mingyang Zhang, Ting Chen, Xun Lu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 100
Brown Adipose Tissue—A Translational Perspective
André C. Carpentier, Denis P. Blondin, François Haman, et al.
Endocrine Reviews (2022) Vol. 44, Iss. 2, pp. 143-192
Open Access | Times Cited: 96
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
Chi Kin Wong, Brent A. McLean, Laurie L. Baggio, et al.
Cell Metabolism (2023) Vol. 36, Iss. 1, pp. 130-143.e5
Closed Access | Times Cited: 88
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 73
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 72
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 70
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 162-173
Closed Access | Times Cited: 67
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
Kimberley El, Jonathan D. Douros, Francis S. Willard, et al.
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 945-954
Open Access | Times Cited: 63
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 59
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 56
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Leili Gao, Byung‐Wan Lee, Manoj Chawla, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1500-1510
Open Access | Times Cited: 50
Impact of treatment with GLP‐1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database
Mahmoud Nassar, Anoop Misra, Zachary T. Bloomgarden
Journal of Diabetes (2024) Vol. 16, Iss. 3
Open Access | Times Cited: 16
Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
Berit Østergaard Christoffersen, Guillermo Sánchez‐Delgado, Linu M. John, et al.
Obesity (2022) Vol. 30, Iss. 4, pp. 841-857
Open Access | Times Cited: 64
Hindbrain circuits in the control of eating behaviour and energy balance
Wenwen Cheng, Desiree Gordian, Mette Q. Ludwig, et al.
Nature Metabolism (2022) Vol. 4, Iss. 7, pp. 826-835
Closed Access | Times Cited: 62
Page 1 - Next Page

Scroll to top